Wren is rapidly advancing a pipeline of small molecule therapeutic candidates, as well as antibody diagnostics, for a number of high-value targets, including alpha-synuclein, amyloid-beta, IAPP, tau and TDP-43.
5 active programmes
Our pioneering network kinetics drug discovery platform gives us the opportunity to explore multiple additional targets of relevance to other protein misfolding disease indications, both in-house and through partnerships with other pharmaceutical companies. We are prioritising protein misfolding diseases with significant unmet medical need, for which no approved disease-modifying treatments currently exist.
Over one thousand articles published to date
Wren’s science has been validated by the world’s leading scientific journals.